Ultrasight

UltrasightUltrasight
Ultrasight

Ultrasight

AI-powered real-time guidance and quality assessment for cardiac ultrasound imaging.

DR 272019Active28Tel Aviv, Israel
Rate

About

Ultrasight develops an AI-powered cardiac ultrasound stewardship platform that provides real-time guidance and quality assessment. Their solution empowers healthcare professionals, regardless of sonography proficiency, to consistently acquire high-quality cardiac ultrasound images at the point of care. This aims to make diagnostic imaging more accessible for patients in various settings, including clinics, hospitals, ambulances, and remote areas.
Frequently asked

What does Ultrasight do?

Ultrasight develops an AI-powered cardiac ultrasound stewardship platform that provides real-time guidance and quality assessment. Their solution empowers healthcare professionals, regardless of sonography proficiency, to consistently acquire high-quality cardiac ultrasound images at the point of care. This aims to make diagnostic imaging more accessible for patients in various settings, including clinics, hospitals, ambulances, and remote areas.

What is Ultrasight's revenue?

StartupHub estimates Ultrasight's annual revenue at $5.3M (range $2.9M to $9.5M, 67% confidence), based on comparable companies in the sector.

What is Ultrasight's valuation?

StartupHub estimates Ultrasight's effective valuation at $61.2M (range $37.5M to $90.0M, 10% confidence), based on comparable companies in the sector.

How much funding has Ultrasight raised?

Ultrasight has raised a total of $15M in funding. The most recent round on record is Series B.

Where is Ultrasight headquartered?

Ultrasight is headquartered in Tel Aviv, Israel.

When was Ultrasight founded?

Ultrasight was founded in 2019.

What industry does Ultrasight operate in?

Ultrasight operates in Healthcare, Medical Imaging, Ultrasound, Cardiac, Sonography, HealthTech.

How many employees does Ultrasight have?

Ultrasight has approximately 28 people on record.

HEADCOUNT
28
DOMAIN RATING
27
Comments

No comments yet. Be the first to share your take.